A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients.

Christian Domingo Ribas Xavier PomaresAlbert NavarroMaría José AmengualConcepción MontónAna SogoRosa M Mirapeix

Published in: British journal of clinical pharmacology (2017)

The OMADORE study found that in more than 50% of SAA patients on OC, OMA dose can be safely reduced or withdrawn based on a progressive dose reduction protocol.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
randomized controlled trial
prognostic factors
multiple sclerosis
patient reported outcomes
lung function
air pollution